Serious neurological events reported with Samsca

The MHRA has warned clinicians of an increased risk of serious neurological events in patients treated with tolvaptan (Samsca).

SIADH is one of the most common causes of hyponatraemia
SIADH is one of the most common causes of hyponatraemia

The selective vasopressin V2-receptor antagonist, tolvaptan (Samsca), is used to treat adults with hyponatraemia secondary to inappropriate antidiuretic hormone secretion (SIADH). However, over-rapid correction of serum sodium can cause osmotic demyelination, resulting in spastic quadriparesis, seizures, coma and death.

Patients at increased risk

MHRA guidelines recommend that serum sodium be closely monitored in patients receiving tolvaptan, especially in those with very low levels (<120mmol/l) at baseline and those at increased risk of demyelination syndromes (eg, as a result of hypoxia, alcoholism or malnutrition).

Monitoring recommendations

Sodium correction greater than 6mmol/l during the first 6 hours of administration or 8mmol/l during the first 6–12 hours may be too rapid. In such cases, close monitoring of serum sodium and administration of hypotonic fluid is recommended. If the increase in serum sodium is greater than 12mmol/l in 24 hours, or 18mmol/l in 48 hours, tolvaptan treatment should be interrupted or discontinued and followed by administration of hypotonic fluid.

Significant interactions

Concomitant treatment with medicines containing high levels of sodium or other treatments for hyponatraemia is not recommended.

Tolvaptan may also interact with and reduce the effect of vasopressin analogues, such as desmopressin, used to prevent or control bleeding.

Further information:

Drug Safety Update April 2012

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more